MaaT Pharma Phase III microbiome trial hits endpoints as stock soar

French clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company’s stock price.